Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023".
作者信息
Zhou Xiao-Dong, Yip Terry Cheuk-Fung, Huang Daniel Q, Muthiah Mark Dhinesh, Noureddin Mazen, Zheng Ming-Hua
机构信息
MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):620-624. doi: 10.3350/cmh.2024.1131. Epub 2024 Dec 26.
Abstract
摘要
相似文献
1
Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023".
Clin Mol Hepatol. 2025 Apr;31(2):620-624. doi: 10.3350/cmh.2024.1131. Epub 2024 Dec 26.
2
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".
Clin Mol Hepatol. 2025 Jan;31(1):277-280. doi: 10.3350/cmh.2024.0823. Epub 2024 Oct 11.
3
Correspondence to editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis".
Clin Mol Hepatol. 2025 Jan;31(1):e61-e63. doi: 10.3350/cmh.2024.0878. Epub 2024 Oct 15.
4
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023".
Clin Mol Hepatol. 2025 Apr;31(2):e180-e182. doi: 10.3350/cmh.2025.0125. Epub 2025 Feb 13.
5
A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
Eur Radiol. 2024 Jun;34(6):3882-3888. doi: 10.1007/s00330-023-10441-5. Epub 2023 Nov 21.
6
Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018.
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1499-1501.e2. doi: 10.1016/j.cgh.2020.08.017. Epub 2020 Aug 12.
7
Towards unification of liver stiffness measurement cutoffs: Editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".
Clin Mol Hepatol. 2025 Jan;31(1):264-267. doi: 10.3350/cmh.2024.0766. Epub 2024 Sep 20.
8
Examining the interim proposal for name change to steatotic liver disease in the US population.
Hepatology. 2023 May 1;77(5):1712-1721. doi: 10.1097/HEP.0000000000000043. Epub 2023 Jan 3.
9
Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.
Int J Mol Sci. 2020 Jun 5;21(11):4039. doi: 10.3390/ijms21114039.
10
Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database.
Adv Ther. 2025 Feb;42(2):1165-1195. doi: 10.1007/s12325-024-03085-4. Epub 2024 Dec 30.
引用本文的文献
1
The association of advanced lung cancer inflammation index with non-alcoholic fatty liver disease in NHANES 2017-2020.
Front Med (Lausanne). 2025 Apr 14;12:1516464. doi: 10.3389/fmed.2025.1516464. eCollection 2025.
2
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023".
Clin Mol Hepatol. 2025 Apr;31(2):e180-e182. doi: 10.3350/cmh.2025.0125. Epub 2025 Feb 13.
本文引用的文献
1
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023.
Clin Mol Hepatol. 2025 Apr;31(2):382-393. doi: 10.3350/cmh.2024.0987. Epub 2024 Nov 29.
2
Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15-39, 1990-2021.
Clin Nutr. 2024 Dec;43(12):391-404. doi: 10.1016/j.clnu.2024.11.016. Epub 2024 Nov 14.
3
Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver disease.
Hepatology. 2025 Jun 1;81(6):1792-1804. doi: 10.1097/HEP.0000000000001121. Epub 2024 Oct 18.
4
Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021.
EClinicalMedicine. 2024 Sep 24;76:102848. doi: 10.1016/j.eclinm.2024.102848. eCollection 2024 Oct.
5
Pharmaco-Economic Assessment of Screening Strategies for High-Risk MASLD in Primary Care.
Liver Int. 2025 Apr;45(4):e16119. doi: 10.1111/liv.16119. Epub 2024 Oct 7.
6
Reproducibility and Repeatability of US Shear-Wave and Transient Elastography in Nonalcoholic Fatty Liver Disease.
Radiology. 2024 Sep;312(3):e233094. doi: 10.1148/radiol.233094.
7
Global burden of metabolic diseases, 1990-2021.
Metabolism. 2024 Nov;160:155999. doi: 10.1016/j.metabol.2024.155999. Epub 2024 Aug 14.
8
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.
Gut. 2024 Oct 7;73(11):1883-1892. doi: 10.1136/gutjnl-2024-333074.
9
Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis.
Clin Mol Hepatol. 2024 Sep;30(Suppl):S199-S213. doi: 10.3350/cmh.2024.0351. Epub 2024 Jul 30.
10
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
Zotero 插件